Activity and Efficacy of Neoadjuvant Chemotherapy in Luminal-HER2 Negative Early Breast Cancer According to HER2 Score (Low vs. Score 0): A Retrospective Study
Among Luminal-HER2 negative early BCs, our results do not support a clear predictive and prognostic effect of HER2 status, although a trend of worse pCR and better survival for HER2 low BCs cannot be ruled out.
Authors
- Giorgia Arcuri
- Armando Orlandi (ORCID: https://orcid.org/0000-0001-5253-4678)
- Noemi Maliziola
- Gianluca Franceschini (ORCID: https://orcid.org/0000-0002-2950-3395)
- Giovanni Scambia (ORCID: https://orcid.org/0000-0002-9503-9041)
- Emilio Bria (ORCID: https://orcid.org/0000-0002-2333-704X)
- Luca Mastrantoni (ORCID: https://orcid.org/0000-0003-1853-4927)
- Alessandra Fabi (ORCID: https://orcid.org/0000-0002-0758-8033)
- Ida Paris
- Giampaolo Tortora (ORCID: https://orcid.org/0000-0002-1378-4962)
- Giovanna Garufi
- Fabio Marazzi (ORCID: https://orcid.org/0000-0003-0977-0143)
- Antonella Palazzo (ORCID: https://orcid.org/0000-0002-8371-7087)
- Antonio Franco (ORCID: https://orcid.org/0000-0003-3411-7015)
- Elena Di Monte
- Valentina Frescura
- Angelachiara Rotondi
- Carbognin Luisa
Institutions
- Università Cattolica del Sacro Cuore (IT)
- Agostino Gemelli University Polyclinic (IT)
Publication Details
- Journal
- Clinical Breast Cancer
- Published
- 2025-03-06
- DOI
- https://doi.org/10.1016/j.clbc.2025.02.016
- Citations
- 4
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 4.18
Funders
- Associazione Italiana per la Ricerca sul Cancro
- Università Cattolica del Sacro Cuore